← FDA Drug Approvals (Drugs@FDA)
EZETIMIBE AND SIMVASTATIN
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: SCIEGEN PHARMS · Approved 2024-12-10
Drug application
- FDA Application #
ANDA211663- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- EZETIMIBE AND SIMVASTATIN
- Generic name
- Ezetimibe
- Active ingredients
- EZETIMIBE; SIMVASTATIN
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Discontinued
- Sponsor
- SCIEGEN PHARMS
- First approval
- 2024-12-10
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown